Icon of the Instituts for Quality and Efficiency in Health Care

[A24-97] Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

Last updated 02.01.2025

Project no.:
A24-97

Commission:
Commission awarded on 23.09.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

First-line treatment of advanced non-small cell lung cancer in adult patients for whom platinum-based chemotherapy is not an option and whose tumours have no EGFR mutations or ALK translocations.

Result of dossier assessment:
  • Patients with PD-L1 expressions ≥ 50% on tumour cells: added benefit not proven.
  • Patients with PD-L1 expressions < 50% on tumour cells: added benefit not proven.
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A24-97

Project no. Title Status
A22-67 Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V Commission completed
A21-69 Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-97 Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-86 Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-84 Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-83 Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-81 Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-88 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Commission completed
A17-52 Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-51 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-102 Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page